August 2019 Vol 10, No 8
Fear and anxiety are unwelcome, although inevitable, occurrences in the initial phases of a cancer diagnosis and can certainly rear their ugly heads again and again along a patient’s journey.
Physical, Psychological, Social, and Spiritual Well-being of Patients and Caregivers Following Lung Cancer Diagnosis: A Scoping Review
Cheryl Bellomo, MSN, RN, HON-ONN-CG, OCN, Amy Jo Pixley, MSN, RN, OCN, ONN-CG, Danelle Johnston, MSN, RN, OCN, HON-ONN-CG
Lung cancer is the second most common cancer in the United States and has been shown to cause considerable symptom burden in both patients and their caregivers.
Navigation’s Impact on Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies
Claire White, BSN, RN, CPHON, Laura Hynes, MA, BSN, RN, Lucy J. Gansauer, MSN, RN, OCN, CCRP, Mary Van Cleave, BSN, RN, OCN, Lavinia Dobrea, RN, MS, OCN, Amy Meleason, BSN, RN, OCN, Daniel McGough, BS, CCRP
What you need to know about discussing clinical trials with your patients.
Pembrolizumab as second-line therapy improved overall survival (OS) in patients with advanced or metastatic esophageal cancer and high PD-L1 expression compared with chemotherapy, according to findings from the phase 3 KEYNOTE-181 study presented at the 2019 Gastrointestinal Cancers Symposium.
Adjuvant Therapy with Durvalumab, a Checkpoint Inhibitor, Shows Promise in Advanced Esophageal Cancer
Adjuvant treatment with durvalumab, a checkpoint inhibitor, in patients with residual disease after trimodal therapy for advanced esophageal or gastroesophageal junction (GEJ) adenocarcinoma was associated with a 79% 1-year relapse-free survival rate in a phase 2 clinical trial.
The era of immunotherapy has opened new perspectives in renal cell carcinoma (RCC), which is one of the tumors most highly infiltrated with cluster of differentiation T cells and PD-1 expression, partially accounting for its sensitivity to immunotherapy.
First-Line Pembrolizumab plus Axitinib Combination Boosts Survival in Metastatic Renal Cell Carcinoma
First-line therapy with pembrolizumab plus axitinib significantly improved overall survival (OS), progression-free survival (PFS), and objective response rates compared with standard-of-care sunitinib in patients with clear cell metastatic renal cell carcinoma (RCC) in KEYNOTE-426.
The combination of the PD-1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab added to best supportive care improved overall survival (OS) by >2 months compared with best supportive care alone in a phase 2 randomized trial of unselected patients with refractory colorectal cancer (CRC).
Results 1 - 10 of 10